Summary & Overview
CPT 90650: Bivalent HPV Vaccine, Intramuscular, Three-Dose
CPT code 90650 denotes a bivalent human papillomavirus (HPV) vaccine administered intramuscularly to protect against HPV types 16 and 18 on a three-dose schedule. Nationally, HPV vaccination codes are central to preventive care initiatives aimed at reducing HPV-related cancers and precancerous lesions. Use of this vaccine code reflects immunization delivery in ambulatory and community settings and factors into public health vaccination coverage metrics.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose of the vaccine and the typical delivery setting, followed by benchmarking and policy-focused content where available. The publication summarizes reimbursement benchmarks, payer coverage patterns, and any notable policy updates affecting vaccine administration and billing practices. It also provides clinical context about the vaccine's target HPV types and the standard three-dose regimen to inform administrative and clinical billing workflows.
Where input data is incomplete, the report notes missing elements and flags areas labeled as "Data not available in the input." The material is presented for a national audience and is intended to support coding accuracy, payer billing alignment, and administrative planning related to CPT code 90650.
Billing Code Overview
CPT code 90650 represents a bivalent human papillomavirus (HPV) vaccine product administered intramuscularly to protect against HPV types 16 and 18. The vaccine is delivered as a three-dose series and is intended to prevent infection with the two high-risk HPV types most commonly associated with cervical and other anogenital cancers.
-
Service type: Vaccine administration (intramuscular immunization)
-
Typical site of service: Outpatient clinics, physician offices, community vaccination centers, and other ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 16-year-old adolescent female presents to a primary care clinic for routine immunizations. The patient is in generally good health, with no acute febrile illness and no history of severe allergic reaction to vaccine components. The clinician confirms this is the first dose of the bivalent human papillomavirus vaccine series and documents informed consent from the patient and parent/legal guardian. The vaccine 90650 (bivalent HPV vaccine, intramuscular, three-dose series) is administered intramuscularly in the deltoid. The clinical workflow includes verifying immunization history, screening for contraindications and precautions, obtaining consent, performing the intramuscular injection, monitoring the patient for 15 minutes post-vaccination for syncope or immediate adverse events, documenting lot number and expiration in the medical record and immunization registry, and scheduling follow-up appointments for dose two and dose three per the manufacturer schedule.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies to the vaccine administration claim |
22 |